In recent years, immunotherapy with immune checkpoint inhibitors (such as anti-PD-1/PD-L1, CTLA-4, and LAG3 monoclonal antibodies) has achieved significant breakthroughs in treating advanced tumors and shown remarkable therapeutic effects in multiple cancer types (5, 6). The gene discussed is PDCD1; the disease is cancer.